Incidence of and Risk Factors for Free Bowel Perforation in Patients with Crohn's Disease

Dig Dis Sci. 2017 Jun;62(6):1607-1614. doi: 10.1007/s10620-017-4539-5. Epub 2017 Mar 17.

Abstract

Background: Incidence of and risk factors for intestinal free perforation (FP) in patients with Crohn's disease (CD) are not established.

Aim: To establish rate of and risk factors for FP in a large cohort of CD patients.

Methods: Medical records of CD patients who visited Asan Medical Center from June 1989 to December 2012 were reviewed. After matching the FP patients to controls (1:4) by gender, year, and age at CD diagnosis, and disease location, their clinical characteristics were compared using conditional logistic regression analysis.

Results: Among 2043 patients who were included in our study cohort, 44 patients (2.15%) developed FP over a median follow-up period of 79.8 months (interquartile range 37.3-124.6), with an incidence of 3.18 per 1000 person-years [95% confidence interval (CI) 2.37-4.28]. All 44 patients underwent emergency surgery, and eight patients underwent reoperation within 12 months (8/44, 18.2%). Multivariable-adjusted analysis revealed that anti-TNF therapy [odds ratio (OR), 3.73; 95% CI 1.19-11.69; p = 0.024] was associated with an increased risk of FP.

Conclusions: The incidence of FP in a large cohort of Korean CD patients was 2.15%, which was similar to that in Western reports. Anti-TNF therapy could be risk factors for FP.

Keywords: Anti-TNF; Crohn’s disease; Intestinal perforation; Stricture.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Colonic Diseases / epidemiology*
  • Colonic Diseases / etiology
  • Colonic Diseases / surgery
  • Crohn Disease / complications
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Female
  • Follow-Up Studies
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Ileal Diseases / epidemiology*
  • Ileal Diseases / etiology
  • Ileal Diseases / surgery
  • Incidence
  • Infliximab / therapeutic use
  • Intestinal Perforation / epidemiology*
  • Intestinal Perforation / etiology
  • Intestinal Perforation / surgery
  • Jejunal Diseases / epidemiology*
  • Jejunal Diseases / etiology
  • Jejunal Diseases / surgery
  • Male
  • Reoperation
  • Republic of Korea / epidemiology
  • Retrospective Studies
  • Risk Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Young Adult

Substances

  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab